Free lookups: 1/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
1 of 3 free lookups remaining Upgrade
New search Medicine profile Povidone iodine/Metronidazole (topical)

Clinical medicine profile

Povidone iodine/Metronidazole (topical)

Antiseptic [EPC]

POM
Evidence state Source-linked Review date not recorded
Route
ORAL / IV / TOPICAL / VAGINAL
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Hypersensitivity to nitroimidazoles.
  • First trimester use traditionally avoided unless essential (practice evolving — follow current obstetric guidance).
  • Disulfiram within 2 weeks.

Precautions

  • Avoid alcohol during and for 24–72 h after (disulfiram-like reaction).
  • Neurologic toxicity with prolonged/high dose (neuropathy, seizures).
  • Metallic taste common.
  • Dark urine possible.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Directions clean the affected area spray a small amount of the product on the area 1 to 3 times daily may be covered with a sterile bandage if bandaged, let dry first

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Metabolites accumulate in renal failure; review dosing in ESRD.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Hepatic metabolism — reduce dose in severe liver disease.

03 Clinical use

Use, effects & interactions

Indications

  • Uses First aid to help prevent infection in minor cuts scrapes burns Clinical selection for Povidone iodine/Metronidazole (topical) should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Antiseptic [EPC].
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • [From component Metronidazole] GI discomfort, anorexia, metallic taste, dry mouth, headache, skin rash, vertigo, depression, insomnia, drowsiness, urethral discomfort, darkened urine, transient fall in BP, temporary leucopenia, bone marrow depression, transient epileptic seizure, furred tongue.
  • Cornerstone for anaerobic coverage and protozoa (giardia, amoeba, trichomonas).
  • Combine with other agents for mixed aerobic–anaerobic infections as indicated.
  • Warn every patient about alcohol.
04 Pharmacology

Mechanism & disposition

Combination product.

Combination product.Component mechanism (Metronidazole): Metro…
Read complete mechanism

Combination product. Component mechanism (Metronidazole): Metronidazole, ornidazole and other imidazoles are selective for anaerobic bacteria due to their ability to intracellularly reduce imidazole which covalently binds to DNA, disrupt its helical structure, inhibiting bacterial nucleic acid synthesis

Onset

1–2 hours

Duration

8–24 hours

Route

ORAL / IV / TOPICAL / VAGINAL

Distribution

including abscesses and CSF. Hepatic

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Widely used in later pregnancy for BV/trichomoniasis in many protocols; avoid unnecessary first-trimester exposure — follow current guidance.

Lactation

Single-dose regimens often compatible with pumping/timing advice; prolonged high dose — review.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; RxNorm (NLM RxNav); Component monographs (multi-source pipeline)
Last reviewedNot recorded
EvidenceSource-linked
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.